efpeglenatide

From Aaushi
Jump to navigation Jump to search

Introduction

Not yet FDA-approved.

Indications

Dosage

  • once weekly injection

Adverse effects

Mechanism of action

More general terms

References

  1. Gerstein HC, Sattar N, Rosenstock J et al Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021 Jun 28; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/34215025 https://www.nejm.org/doi/10.1056/NEJMoa2108269